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Abstract
It is well known that the outcome of an intervention is affected both by the inherent effects of the intervention and the
patient’s expectations. For this reason in comparative clinical trials an effort is made to conceal the nature of the
administered intervention from the participants in the trial i.e. to blind the trial. Yet, in practice perfect blinding is impossible
to ensure or even verify post hoc. The current clinical standard is to follow up the trial with an auxiliary questionnaire, which
allows trial participants to express in closed form their belief concerning the intervention, i.e. trial group assignment
(treatment or control). Auxiliary questionnaire responses are then used to compute the extent of blinding in the trial in the
form of a blinding index. If the estimated extent of blinding exceeds a particular threshold the trial is deemed sufficiently
blinded; otherwise, the strength of evidence of the trial is brought into question. This may necessitate that the trial is
repeated. In this paper we make several contributions. Firstly, we identify a series of problems of the aforesaid clinical
practice and discuss them in context of the most commonly used blinding indexes. Secondly, we formulate a novel
approach for handling imperfectly blinded trials. We adopt a feedback questionnaire of the same form as that which is
currently in use, but interpret the collected data using a novel statistical method, significantly different from that proposed
in the previous work. Unlike the previously proposed approaches, our method is void of any ad hoc free parameters and
robust to small changes in the participants’ feedback responses. Our method also does not discard any data and is not
predicated on any strong assumptions used to interpret participants’ feedback. The key idea behind the present method is
that it is meaningful to compare only the corresponding treatment and control participant sub-groups, that is, sub-groups
matched by their auxiliary responses. A series of experiments on simulated trials is used to demonstrate the effectiveness of
the proposed approach and its superiority over those currently in use.
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Introduction
Ultimately, the main aim in a clinical trial is straightforward: it
is to examine and quantify the effectiveness of a treatment of
interest. Effectiveness is evaluated relative to the effectiveness of a
particular reference, the so-called control intervention. The form
that the control intervention takes is dependent on the nature of
the treatment which is studied. Since the goal of any newly
proposed treatment is to better those which are already available
and practiced, the common standard is to make the comparison
with the current best alternative. In some instances this may be no
active intervention at all.
Controlling and Blinding Trials
To ensure that the aforementioned comparison is meaningful, it
is of essential importance to ensure that any factors not inherently
associated with the two interventions (treatment a‘nd control) are
normalized (controlled) between the two groups. This ensures that
the observed differential outcome truly is the effect of differing
interventions rather than any orthogonal, confounding variables.
A related challenge is that of blinding (or masking). Blinding
refers to the concealment of the type of administered intervention
from the individuals/patients participating in a trial and its aim is
to eliminate differential placebo effect between groups [1–3].
Although conceptually simple, the problem of blinding poses
difficult challenges in a practical clinical setup. We highlight two
specific challenges which most strongly motivate the work of the
present paper. The first of these stems from the difficulty of
ensuring that absolute blinding with respect to a particular trial
variable is achieved. The second challenge arises as a consequence
of the fact that blinding can only be attempted with respect to
those variables of the trial which have been identified as revealing
of the treatment administered. Put differently, it is always possible
that a particular variable which can reveal the nature of the
treatment to a trial participant is not identified by the trial
designers and thus that no blinding with respect to it is attempted
or achieved. This is a ubiquitous problem, present in every
controlled trial, and one which can severely affect the trial’s
outcome.
Assessing Blinding
Given that it is both practically and in principle impossible to
ensure perfect blinding, the practice of assessing the level of
blinding after the commencement of a trial has been gaining
popularity and general acceptance by the clinical community
[4,5]. The key idea is to use a statistical model and the
participants’ responses to a generic questionnaire to quantify the
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participants’ knowledge about the administered intervention.
While the statistical model used to this end has been a source of
disagreement between researchers, as discussed in detail in the
‘‘Previous Work’’ section, the general approach is shared by
different methods described in the literature. In this paper we
argue that this common approach suffers from several important
limitations:
(i) it necessitates the inclusion of ad hoc free parameters in the
underlying statistical model,
(ii) the assumptions underlying the interpretation of the
auxiliary questionnaire responses are not universally
upheld,
(iii) the blinding assessment can be highly sensitive to small
changes in the participants’ questionnaire responses, and
(iv) it leads to a sequential separation of inference concerning
the extent of trial blindness and the assessment of
differential effectiveness of the treatment.
Motivated by these key limitations of previous work, in the
present work we propose a novel statistical framework and use it to
derive an original method for integrated trial assessment which is
experimentally shown to produce more meaningful and more
clearly interpretable data. One of the key ideas behind the present
method is that it is meaningful to compare only the corresponding
treatment and control participant sub-groups, that is, sub-groups
matched by their auxiliary responses. The inference of the
differential effect of treatment is then achieved through Bayesian
analysis.
Paper Organization
The remainder of this paper is organized as follows. In the next
section we describe the design of auxiliary data collection and
review the most influential methods in the literature which use this
data to assess participants’ blindness in a trial. The main
limitations of previous work are discussed in detail in this section
as well. The proposed methodology, the conceptual idea behind it
and the key mathematical formulae, are introduced subsequently.
This is followed by a series of experiments which are used to
illustrate systematically the advantages of our method. Finally, a
further discussion of experimental results and the accepted clinical
practices is presented before the manuscript is concluded with a
summary of our main contributions and the possible avenues for
further work.
Previous Work
In this section we describe the general methodology of auxiliary
data collection, the two most influential statistical models which
use the aforesaid data to quantify the extent of blinding in a trial,
and discuss the key limitations of the existing approaches which
motivate the work described in the present paper.
Method 1: James’s Blinding Index
At the heart of the so-called blinding index proposed by James et
al. [6] is the observation that the effect of a particular intervention
is affected by the participant’s perception of the effectiveness of the
intervention the participant believes was administered. For
example, a control group member who incorrectly believes to be
a member of the treatment group may indeed experience positive
effects expected from the studied treatment. The is the well-known
and extensively studied placebo effect [7,8]. Similarly, a treatment
group member who incorrectly believes to be a member of the
control group may experience treatment effects less pronounced
than in the case of the correct assignment guess, or indeed than in
the case of absence of a belief either way.
Design of Auxiliary Data Collection. James et al. propose
the use of a post-trial questionnaire (the contentious issue of the
timing of the questionnaire is discussed in the ‘‘Interpretation of
Participants’ Feedback’’ section) to assess the level of blinding in
the trial. Following the trial, in its basic form the questionnaire asks
the trial participants to state if they believe that they were assigned
to:
(i) the control group,
(ii) the treatment group, or
(iii) if they are uncertain of their membership (the ‘‘don’t know’’
response).
Extensions of this scheme which attempt to harness more
detailed information have also been used, for example allowing the
participants to quantify the conviction of their belief as ‘‘weak’’ or
‘‘strong’’. In that case, the questionnaire would offer five choices:
(i) strong conviction of belonging to the control group,
(ii) weak conviction of belonging to the control group,
(iii) strong conviction of belonging to the treatment group,
(iv) weak conviction of belonging to the treatment group,
(v) uncertain membership (the ‘‘don’t know’’ response).
More granular auxiliary data choices have the potential of
providing a more accurate picture of the extent of blinding.
However, depending on the statistical model used, this advantage
may come at the cost of reduced statistical significance for each of
the response sub-groups (see the ‘‘Methods’’ section).
Quantifying the Extent of Blinding. For the sake of clarity
of presentation, we use the same mathematical notation through-
out the paper. The key symbols and their meanings are
summarized for the benefit of the reader in Table 1.
The existing work on the assessment of blinding in trials uses the
collected auxiliary responses to calculate a statistic referred to as
the blinding index. For a 3-tier auxiliary questionnaire, James et al.
[6] define their blinding index r1 as:
r1~
1
2
½1zP0z(1{P0):D  ð1Þ
It can attain values in the interval ½0,1, higher values denoting
increasing levels of blindness. Thus r1~1 indicates perfect
blinding and r1~0 an unblinded trial. It can be seen that r1 in
Equation 1 comprises two non-constant terms. The first of these is
the estimate P0 of the probability of the ‘‘don’t know’’ response.
From the collected questionnaire responses, P0 can be computed
as follows:
P0~
n0
n{zn0znz
~
n0
n
ð2Þ
where n is the total number of participants in the trial, and n{, n0
and nz respectively the numbers of participants who believe that
they were assigned to the control group, those who were uncertain
of their assignment and those who believe that they were assigned
to the treatment group. As the value of P0 is increased so is its
contribution to the blinding index through the first term in
Equation (1). This fits the intuition that in a perfectly blinded trial
participants should be entirely ignorant of the group they were
assigned to, that is to say, of the intervention they were
administered.
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The second term contributing to the blinding index is
proportional to the statistic D which takes into account the
distribution of participants who do have a positive or negative
belief regarding their assignment, that is, who believe to belong to
either the control or the treatment group. James et al. define D as:
D~
X
a[fP,Tg
X
g[fz,{g
vag
Pag(1{P0){Pg(Pa{Pa0)
(1{P0)
2
ð3Þ
In Equation (3), the constants vag are weighting coefficients. In
this expression their effect is to scale relative contributions of the
correct and incorrect group assignment guesses. To gain intuitive
insight into the nature of the D statistic, consider the plot shown in
Figure 1(a). From the plot, it is readily apparent that r1 is a
concave function which attains its maximal value of 1:0 when (i) all
participants are uncertain of their assignment (i.e. P0~1) or (ii)
when all participants have an incorrect belief regarding their
assignment (i.e. PTz~PC{~0). Expressed formally:
r1~1uP0~1 _ PTz~PC{~0 ð4Þ
In comparison with the case of P0~1 the attainment of the
maximal value r1~1 for PTz~PC{~0 is more questionable.
While it is tempting to reason that blinding must have been
successful since no participant correctly guessed their assignment,
it would be erroneous to do so. In particular, the consistency of the
wrong belief amongst trial participants actually reveals unblinding,
but with the participants’ incorrect association of the unblinded
factor with the corresponding group assignment. For example, the
treatment may cause perceivable side effects (thus unblinding the
participants) and the worsening of the condition of the treatment
group participants. This observation could incorrectly lead them
to the conclusion that they were assigned to the control group.
This problem was also discussed by Bang et al. [9].
Method 2: Bang’s Blinding Index
As explained in the discussion of the previous section, the
blinding index of James et al. places a lot of value on those
participants who plead ignorance regarding their assignment
status. Bang et al. see this as a limitation [9]. Specifically, it can be
argued that the non-decisive, ‘‘don’t know’’ response may not
express a true lack of knowledge by the corresponding partici-
pants, but rather that it is a conservative response, an answer born
out of the participants’ desire to appear balanced in their
judgement. Thus, Bang et al. propose an alternative statistic which
instead most heavily weights the contribution of decisive responses. In
addition, because decisive responses can be in either the positive or
the negative direction (i.e. belief in treatment or control
intervention), Bang’s blinding index is asymmetrical and can be
applied separately to treatment and control groups. For a 3-tier
auxiliary questionnaire, in its simplest form the index for the
treatment group is defined as:
r’2~ 2
PC{
PC{zPT{
{1
 
: PT{zPTzP
g[{,0,z PTg
ð5Þ
and similarly for the control group:
r
0
2~ 2
PC{
PC{zPT{
{1
 
: PC{zPCzP
g[{,0,z PCg
ð6Þ
The general form of this index, which applies weighting to
different responses in a manner similar to James et al. can be found
in the original paper [9].
The behaviour of this index can be seen in Figure 1(b) which
plots it against the proportions of indecisive responses and correct
guesses. It is readily apparent that the plot has a form very
different from that in Figure 1(a) showing the corresponding
variation of r1. Firstly, note that unlike r1, the range of values for
r2 is ½{0:5,0:5. The value of r2~0 indicates perfect blinding,
r2~0:5 an unblinded trial and r2~{0:5 an unblinded trial with
incorrect assignment association, as discussed previously.
As the plot shows, this index achieves its perfect blinding value
only when P0~1. Unlike r1, the case when PTz~PC{~0 does
not necessarily result in perfect blinding. Also, PTz~PC{~1
and P0~0 deems the trial unblinded, as does PTz~PC{~0 and
P0~0 but with the incorrect assignment association. Contrast this
with the corresponding value of r1.
Limitations of the Current Best Standards
In the preceding sections we described the two statistics,
blinding indexes, most widely used in practice to assess the level of
blinding in controlled clinical trials. To highlight and motivate the
contribution of the present work, we now analyze both the
inherent and practical limitations of the aforesaid methodologies.
Adjustment of Free Parameters
One of the most obvious difficulties encountered when applying
either of the described blinding indexes concerns the need to
Table 1. Notational convention for mathematical symbols adopted in this paper.
Symbol Description
a subscript modifier specifying group assignment; a[fC,Tg: a~C signifies control
group assignment and a~T signifies treatment group assignment
g subscript modifier specifying membership belief; g[f{,0,zg: g~{ signifies belief
in control group membership, g~0 signifies uncertainty and g~z signifies belief
in treatment group membership
Pag proportion of participants who were assigned to the group a and who believe their
membership to be g
Pa proportion of participants who were assigned assigned to the group a
Pg proportion of participants who believe their group membership to be g
height 4
doi:10.1371/journal.pone.0048984.t001
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choose appropriate values for the free parameters in Equation (3),
and Equations (5) and (6) in their general form. These are the
weighting constants wag. Recall that their purpose is to scale the
relative contributions of different responses. For example, James et
al. propose the ratio of 0:5 : 1 or 0:75 : 1 of weights corresponding
to, respectively, incorrect assignment guesses and ‘‘don’t know’’
responses. Equally, if a questionnaire with more than 3 choices is
used, the contribution of the participant’s response is scaled
according to the corresponding level of conviction expressed.
Thus, qualitatively speaking, a response indicating a weak belief in,
say, control group assignment, could be interpreted to fall
somewhere between a ‘‘don’t know’’ response and a strong belief
in control group assignment.
Although not without an intuitive appeal, a thorough analysis of
this ad hoc approach reveals a series of problems, both inherent and
practical. Firstly, there is no objective underlying mechanism
which would explain why the contributions of different responses
should be combined linearly at all. What is more, even if linear
combination is adopted, it is inherently the case that there is no
principled method of choosing the values of the weighting
constants – the lack of observable ‘‘ground truth’’ means that it
is not possible to objectively compare the quality of different
predictions. The last subtle point but of pervasive practical
importance, is that the values of ‘‘best’’ weighting constant ratios
are likely to differ from trial to trial, that is, depending on the
nature of the administered treatment and the implementation of
the control intervention.
All of the aforestated difficulties encountered in the choice of the
free parameters necessary to compute the two blinding indexes
become even more obvious, practically significant and complex as
the questionnaire becomes more detailed (for example by using a
9-tier feedback or by asking the participants to rate the confidence
of their response on a scale of 1 to 10, say). Consequently and
contrary to what ought to be the case, having better, more detailed
feedback data can actually result in a worse assessment of blinding
due to inappropriate free parameter choices.
Interpretation of Participants’ Feedback
It is important to highlight that both the index of James et al. as
well as that of Bang et al. use the same type of feedback data
collected from the trial participants – the participants’ stated belief
regarding their trial group assignment and the degree of
confidence in this belief. Where the two approaches differ in is
the interpretation of the participants’ answers.
James et al. interpret the non-decisive, ‘‘don’t know’’ response as
indicative of true lack of knowledge regarding the nature of the
intervention (treatment or control). If the trial participants are
ignorant of their group assignment, it is assumed that they have
indeed been blinded. Consequently, the index of James et al. most
heavily relies on the proportion of the non-decisive participants.
However, as Bang et al. point out, the ‘‘don’t know’’ response may
not truly represent lack of knowledge. Instead, this response may
be seen as a conservative one, reflecting the participants’ desire to
appear balanced in their judgement or indeed the response that
the participants believe would please the trial administration staff
the most. Thus, Bang’s blinding index mostly relies on the
responses of those trial participants who did express belief
regarding their group assignment. Blindness is measured by
comparing the observed statistics of decisive responses with those
expected from an ideal, fully blinded trial. However, this
interpretation of participants’ responses is readily criticized too.
As Hemilia¨ amongst others notes, because the participants’
feedback is usually collected post hoc i.e. after the trial, it is possible
that even a perfectly blinded subject, who thus did not experience
the placebo effect, becomes aware of the correct assignment by
virtue of observing the effects (or lack thereof) of the assigned
intervention [10]. Considering the same issue, Henneicke-von
Zepelin [11] suggested that auxiliary data should be collected
before or shortly after the commencement of a trial. However, this
is in most cases unsatisfactory as the participants would not have
yet been exposed to any unblinded aspects of the trial. As we
demonstrate in the next section, the approach proposed in this
paper avoids this problem.
Sensitivity to Small Input Differences
Both James et al. and Bang et al. establish the level of blindness in
a trial by computing a statistic, the blinding index, and then
comparing it with a predefined threshold. For example, if r1 is
smaller than the threshold value, the trial is considered insuffi-
ciently well blinded; if the blinding index exceeds the threshold,
the trial is considered sufficiently well blinded. The value of r2 is
interpreted in the same way, with the difference that thresholding
Figure 1. Plot showing the dependency of the blinding indexes (a) r1 proposed by James et al. [6] and (b) r
’
2 proposed by Bang et al.
[9] on the proportions of ‘‘don’t know’’ responses P0, and the correct assignment guesses PTz and PC{. Note that although PTz and
PC{ are independent variables, due to their symmetric contributions and for the purpose of easier visualization, in this plot it was taken that PTz
and PC{ were always equal (making the plot readily representable in 3D instead of 4D).
doi:10.1371/journal.pone.0048984.g001
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is done in the opposite direction and on the absolute value of the
index.
This hard thresholding whereby a trial is considered either
sufficiently well blinded or not means that in some instances the
outcome of the blinding assessment can exhibit high sensitivity to
small differences in participants’ responses. The response of a
single individual can change the assessment outcome. Yet, such
binarization in some form is necessitated by the nature of the
blinding indexes because neither of the two described statistics has
a clear practical interpretation in the clinical context.
The task of choosing the value of the aforesaid threshold suffers
from much the same problems as the task of selecting the values of
the weighting constants, discussed in the ‘‘Adjustment of Free
Parameters’’ section – inherently, there is no objective and
meaningful way of defining the optimal threshold value, and the
value actually selected by the practitioner is likely to vary from trial
to trial.
Inference Atomization
The problem of high sensitivity to small input differences
considered previously is but one of the consequences of the inference
atomization. To clarify the issue at hand, consider the diagram in
Figure 2. This diagram summarizes the process of trial data
interpretation, placing the assessment of blinding in the overall
clinical context. Specifically, observe that the analysis of the trial
outcome data is separated from the blinding assessment. If the
blinding index falls short of the predetermined threshold,
regardless of by how much, the strength of evidence of data is
brought into question and the trial may need to be repeated. On
the other hand, if the blinding index exceeds the threshold, the
analysis of data is performed in the same manner regardless of the
actual value of the index, that is, regardless of whether it is just
above the threshold or if it indicates perfect blinding.
The variety of problems that emerges from the atomization of
different statistical aspects of a trial is inherently rooted in the very
nature of the framework adopted by James et al. and Bang James et
al. alike. As stated earlier, neither of the two indexes has a clear
practical interpretation in the clinical context. For example,
neither tells the clinician the probability that a particular portion
of the participants were unblinded, nor the probability of a
particular level of unblinding. Instead, from the point of view of a
clinician, the blinding index behaves like a black box which deems
the trial well blinded or not, with little additional insight.
Methods
Having analyzed the limitations of the current clinical practices
used to assess blinding, we now turn our attention to the most
important contribution of this paper – a principled method for
inference from collected trial data. We first introduce a statistical
model underlying our approach, followed by the key results. For
clarity, the full mathematical derivation of all the results is
included in Appendix.
Study Design and Outcome Model
As we demonstrated in the previous section, many of the
problems of the approaches proposed by James et al. and Bang et
al. inherently stem from the underlying statistical model. Although
our approach uses the same type of participants’ feedback data,
our statistical model differs significantly from that employed in
previous works.
In the general case, the effectiveness of a particular intervention
in a trial participant depends on the inherent effects of the
intervention, as well as the participant’s expectations (conscious or
not). Thus, in the interpretation of trial results, we separately
consider each population of participants which share the same
combination of the type of intervention and the expressed belief
regarding this group assignment. For example, when a 3-tier
questionnaire is used in a trial comparing the administration of the
treatment of interest and control, we recognize 3|2~6 sub-
groups:
(i) participants of the control group who believe they were
assigned to the control group (subgroup GC{),
(ii) participants of the control group who are unsure of their
group assignment (subgroup GC0),
(iii) participants of the control group who believe they were
assigned to the treatment group (subgroup GCz),
(iv) participants of the treatment group who believe they were
assigned to the control group (subgroup GT{),
(v) participants of the treatment group who are unsure of their
group assignment (subgroup GT0), and
Figure 2. The current clinical practice separates the task of assessing the degree of blinding in a trial from the comparative analysis
of the effectiveness of different interventions studied. The effectiveness of the treatment of interest is only analyzed if the trial is first deemed
to have been sufficiently blinded. In contrast, the proposed methodology concurrently employs all available information. By doing this, our approach
is able to deal with the entire continuum of different levels of blinding, never discarding information.
doi:10.1371/journal.pone.0048984.g002
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(vi) participants of the treatment group who believe they were
assigned to the treatment group (subgroup GTz).
This is conceptually illustrated in Figure 3. In the general case,
for an N-tier questionnaire andM different intervention types, we
can distinguish between N|M distinct sub-groups of participants.
A key idea of the proposed method is that because the outcome
of an intervention depends on both the inherent effects of the
intervention and the participants’ expectations, the effectiveness
should be inferred in a like-for-like fashion. In other words, the
response observed in, say, the sub-group of participants assigned to
the control group whose feedback professes belief in the control
group assignment should be compared with the response of only
the sub-group of the treatment group who equally professed belief
in the control group assignment. Similarly, the ‘‘don’t know’’ sub-
groups should be compared only with each other, as should the
subgroups corresponding to the belief in the treatment assignment.
Ideas similar in spirit were expressed by Berger in the consider-
ation of the related problem of so-called selection bias and
specifically the Berger-Exner test [12]. However, the manner in
which these ideas are formalized statistically in the present paper is
entirely different, the methods described by Berger sharing many
of the weaknesses of the approaches of James et al. and Bang et al.,
which were analyzed in detail in the ‘‘Limitations of the Current
Best Standards’’ section. The proposed approach is formalized
next.
Inference
Consider two corresponding sub-groups, that is, sub-groups
corresponding to different types of received intervention but the
same response in the participants’ feedback questionnaire.
Furthermore, let the benefit of an intervention observed in a
particular participant be expressed as a real number x(i)ag. Thus,
and without loss of generality, a greater x(i)ag indicates greater
benefit. For example, xi may represent the amount of fat loss in a
fat loss trial, the reduction in blood plasma LDL in a statin trial
etc. Our goal is to infer p(Dx), that is, the probability density
function over the difference Dx in the benefit observed across the
two compared sub-groups.
Let DCg be the trial outcome data collected from a control sub-
group and DTg of the matching treatment sub-group.
DCg~ x
(1)
Cg, . . . ,x
(nCg )
Cg
n o
ð7Þ
DTg~ x
(1)
Tg, . . . ,x
(nTg)
Tg
n o
ð8Þ
Then, if Dg~DCg|DTg is the totality of all data of participants
who believe they were assigned to the group g, by applying Bayes
rule we can write the following:
p(Dx D Dg)~
P(Dg D Dx) p(Dx)
p(Dg)
: ð9Þ
Modelling the response of each sub-group using a normal (i.e.
Gaussian) distribution
x
(i)
Cg*N (mCg,sg) and x(j)Tg*N (mTg,sg) ð10Þ
and remembering that for the underlying distributions it holds that
mCgzDx~mTg, allows us to further write
p(Dx D Dk)! p(Dg D Dx)~ ð11Þ
ð
mCg
ð
sg
p(Dg D Dx,mCg,sg) p(mCg) p(sg) dsg dmCg ð12Þ
where p(mCg) is a prior on the mean of the control sub-group and
p(sg) a prior on the standard deviation within sub-groups. What
Equation (12) expresses is the process of probability density
function marginalization over nuisance variables mCg and sg.
Since the values of these latent model variables are unknown,
marginalization takes into account all of the possibilities and
weights them in proportion to the supporting evidence.
As shown in full detail in Appendix 0, when two corresponding
sub-groups of participants are considered, for uninformed priors
over mCg and sg, the posterior distribution of Dx is given by:
p(Dx D Dg)!c
{
nCgznTg{1
2
g ~c
{
ng{1
2
g ð13Þ
where constant scaling factors have been omitted for clarity, and
Figure 3. A conceptual illustration of the proposed statistical model for the 3-tier participants’ feedback questionnaire: (i) belief in
treatment assignment, (ii) belief in control assignment and (iii) uncertain (‘‘don’t know’’). Dotted and solid lines show respectively the
probability density functions of the measured trial outcome across individuals in the three control and treatment sub-groups. Parameters sg and mag
denote the corresponding standard deviation and the mean of each sub-group, and Dx the differential effect of treatment.
doi:10.1371/journal.pone.0048984.g003
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cg~
XnCg
i~1
x
(i)2
Cgz
XnTg
j~1
(x
(j)
TgzDx)
2{
PnCg
i~1 x
(i)
Cgz
PnTg
j~1 (x
(j)
TgzDx)
h i2
nCgznTg
ð14Þ
Extending to the joint inference over the entire data corpus, the
posterior can be computed simply as a product of all sub-group
pair posteriors (up to a scaling constant):
p(Dx D |gDg)!P
g
p(Dx D Dg)!P
g
c
{
ng{1
2
g ð15Þ
The estimate of the posterior distribution of Dx in Equation (15) is
the best estimate that can be made using the available data, and it
is of the most interest to the clinician. However, as we will discuss
in the ‘‘Discussion’’ section, both Equation (13) and Equation (15)
have significance in the interpretation of trial results and their joint
consideration can be used to reveal important additional
information about the effectiveness of the treatment.
Results
Certain advantages of the proposed methodology, in compar-
ison to the approaches of James et al. and Bang et al. are ipso facto
inherent in the theory developed in the preceding sections. The
absence of free parameters is one such advantage. Other claimed
properties of the method, such as its robustness to small input
differences (i.e. differences in the patients’ feedback responses), are
not immediately obvious. Thus, in this section we present the
results of a series of experiments which demonstrate the superiority
of the proposed method.
Evaluation Methodology
In contrast to the methods of James et al. and Bang et al. which
do not attempt to infer any objective and measurable quantity, the
proposed approach pools all available data (trial outcomes and
auxiliary questionnaire feedback) in an effort to evaluate robustly
the effectiveness of the studied treatment. This feature of our
method allows us to directly evaluate its performance. Specifically,
we employ a computer-based simulation whereby data is first
randomly (or rather pseudo-randomly) generated using a statistical
model with adjustable parameters, followed by the application of
the proposed method which is used to infer the said parameters.
The values inferred by our method can then be directly compared
with their known true values.
Experiment 1: Reference. For our first experiment, we
simulated a trial involving 200 individuals, half of which were
assigned to the control and half to the treatment group. For each
of the groups, 60% of the participants were taken to be in the
‘‘undecided’’ subgroups GC0 and GT0. The remaining 40% of the
participants was split between correct and incorrect guesses of the
assigned intervention in proportion 3 : 1. This is summarized in
Table 2. In this initial experiment we assume that all participants
correctly disclosed their belief regarding which group they were
assigned to. Note that this assumption is done purely in the process
of generating data for the experiment – neither this nor any of the
preceding information is used by our method to analyze the
outcome of the trial.
We set the differential effect of treatment to Dx~0:1 and the
standard deviation of variability within each of the assignment-
response subgroups (please refer back to the ‘‘Study Design and
Outcome Model’’ section) also to s{~s0~sz~0:1. Relative to
genuine lack of belief in either control or treatment group
assignments, belief in control group assignment was set to exhibit
negative effect of magnitude 0:2 (i.e. {0:2) and that in treatment
group assignment a positive effect of magnitude 0:2. Experimental
parameters are summarized in Table 3.
Intervention outcomes were then generated by repeated
random draws from the corresponding distributions. For example,
the outcome associated with a participant in the group GC{ was
determined by a random draw from the normal distribution
N (mC{,s{). The outcomes thus obtained are detailed in Table 4
and visually illustrated in Figure 4.
The result of applying the proposed method is summarized in
Figure 5 which plots the posteriors corresponding to the three
subgroups matched by the patients’ belief and the amalgamated
posterior. The same plot also marks the maximum a posteriori (MAP)
value Dx of the estimate of the differential effectiveness of the
treatment:
Dx~arg max
Dx
p(DxD )&0:107 ð16Þ
which is very close to the true value of Dx~0:1.
In comparison, when the differential effectiveness is estimated
by subtracting the mean response of the control group from that of
the treatment group, without the use of our matching sub-groups
based statistical model, the estimate Dx is:
Dx~
X
g[f{,0,zg
PTgxTg{PCgxCg
 
&0:141, ð17Þ
where xag is the mean effectiveness across the subgroup Gag:
xag~
1
nag
Pnag
i~1
x(i)ag: ð18Þ
Finally, the corresponding values of the blinding indexes proposed
by James et al. and Bang et al. are:
r1~0:53 r’2~r’’2~0:10 ð19Þ
Notice that the former indicates a level of blinding roughly half
way between a perfectly blinded and unblinded trial, while the
latter deems the trial nearly perfectly blinded.
Experiment 2: Conservative Distortion. In the ‘‘Interpre-
tation of Participants’ Feedback’’ it was explained why the
participants in a trial may not be fully honest in their auxiliary
questionnaire feedback and how this presents a major problem in
formulating a universally correct statistical model. For example,
there may be a conservative drift towards the middle whereby
participants falsely declare uncertainty towards their group
assignment out of desire of appearing balanced in their judgement.
It was argued on theoretical grounds that the proposed
methodology presents a universal framework for controlled trial
assessment and analysis, and as such is robust to the aforemen-
tioned phenomenon. Here we investigate this claim experimen-
tally.
We modify the baseline experiment described in ‘‘Experiment 1:
Reference’’ by simulating conservative behavioural tendency of
participants in a trial. This was achieved by randomly choosing
individuals from decisive subgroups (GC{, GCz, GT{ and GTz)
and re-assigning them to their corresponding indecisive subgroup
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without changing their treatment’s observed effectiveness. Thus, a
randomly chosen participant from subgroups GC{ or GCz would
be assigned to the subgroup GC0 and one from subgroups GT{ or
GTz to GT0. The probability of re-assignment was set to
pcons~0:2.
As before, we applied the proposed method on the modified
data and display the key results in Figure 6. In addition to the new
subgroup posteriors (dotted lines), for comparison in Figure 6 (a)
we also show the three initial subgroup posteriors from Experi-
ment 1 (solid lines). The baseline (thick solid line) and new (thin
solid line) amalgamated posteriors are shown in Figure 6 (b).
Figure 6 (b) also shows the semi-amalgamated posterior obtained
using only decisive subgroups which, by experimental design,
comprise data of only those individuals which honestly disclosed
their belief of group assignment. The new MAP value for the
differential effectiveness using the amalgamated posterior can be
seen to be Dx&0:122 and that using the semi-amalgamated
posterior Dx&0:116. In the ‘‘Further Clinical Insight’’ section we
will show how the difference in statistical features of sub-group
posteriors can be used to select the most reliable posteriors to
amalgamate, as well as to reveal additional insight into the nature
of the studied treatment and the blinding in the trial.
The conventionally measured mean differential effect remains
unaffected by the conservative distortion; however, the assessment
of sufficient blinding does not (this is discussed in detail in the
‘‘Discussion’’ section).
Experiment 3: Asymmetric Progressive
Unblinding. One of the unappealing consequences of inference
atomization, i.e. the separation of blinding assessment and the
actual trial outcome, adopted by James et al. and Bang et al. alike,
becomes readily apparent when the effects of small differences in
the patients’ feedback responses are considered. On the one hand,
as long as the blinding index stays above or below the chosen
threshold, a small difference in the patients’ feedback (e.g. the
change in a single individual’s response) is of no consequence to
the subsequent analysis of the actual trial data. On the other hand,
for the values of the blinding index near the chosen threshold, an
equally small input difference can result in the complete rejection
of trial data, due to insufficient blinding. In this experiment and in
Experiment 4 we examine the behaviour of the proposed method
as its input in the form of the trial participants’ auxiliary data is
progressively altered.
Starting with the baseline setup of Experiment 1, we simulate
unblinding of previously undecided individuals of the treatment
group. In other words, in each turn we re-assign an individual
from the subgroup GT0 to the subgroup GTz and compute the
novel distribution for Dx. We call this experiment asymmetric
progressive unblinding because only the treatment group participants
are being unblinded (symmetric unblinding is considered in
‘‘Experiment 4: Symmetric Progressive Unblinding’’).
Figure 7 (a) shows the initial posterior p(DxD ) (bold line) and a
series of posteriors after a greater and greater number of
previously blinded participants were unblinded. The obtained
posteriors demonstrate the robustness of the proposed approach,
with small random variations as expected in any practical
experiment involving stochastic data. The resilience of the method
is further corroborated in Figure 7 (b), which shows the maximum a
posteriori estimate of the effectiveness of the treatment (i.e. the mode
of the posterior). This estimate also only shows small random
perturbations, with the corresponding standard deviation of only
0:0054. The plots in Figure 8 show the variation of the two
blinding indexes throughout the experiment. As expected from the
change in the participants’ auxiliary data, both indexes change in
value dramatically. The index of James et al. decreases, while that
of Bang et al. increases in absolute value, indicating agreement on
the lowered level of blinding.
Experiment 4: Symmetric Progressive
Unblinding. Finally, in the last simulated experiment, we
consider the effects of unblinding previously blinded trial
participants from both the treatment and the control group. Notice
that this results in a progressively more unbalanced distribution of
individuals in the two groups across the corresponding sub-groups.
This is important because of the matching sub-group comparison
at the heart of the proposed approach (see the ‘‘Methods’’ section)
and is discussed in detail in the next section.
As in Experiment 3 we start with the baseline setup of
Experiment 1 and simulate unblinding of previously undecided
individuals of the treatment group. In each turn of progressive
unblinding we re-assign an individual from the subgroup GT0 to
the subgroup GTz and an individual from the subgroup GC0 to
the subgroup GC{, and compute the novel distribution for Dx. We
call this experiment symmetric progressive unblinding because both the
treatment group and the control group participants are being
unblinded (asymmetric unblinding was considered in ‘‘Experiment
3: Asymmetric Progressive Unblinding’’).
We illustrate the robustness of the method by plotting the
maximum a posteriori estimate of the effectiveness of the treatment
(i.e. the mode of the posterior) in Figure 9. As before, the estimate
Table 2. A summary of the trial size, the split of participants into groups and their auxiliary subgroups, used to generate data for
the initial experiment.
n nC nT PC{ PC0 PCz PT{ PT0 PTz
200 100 100 0.3 0.6 0.1 0.1 0.6 0.3
doi:10.1371/journal.pone.0048984.t002
Table 3. The ground truth parameters of the underlying distributions used to generate intervention outcomes for participants in
our simulated trial.
Dx mC{ mC0 mCz mT{ mT0 mTz s{ s0 sz
0.1 20.2 0.0 0.2 20.1 0.1 0.3 0.1 0.1 0.1
The reader may find it useful to refer back to Figure 3.
doi:10.1371/journal.pone.0048984.t003
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Table 4. Automatically generated data for the simulation trial used to assess the proposed method.
Group Subgr. Observed intervention outcome/effectiveness (per individual)
Control group GC{ 0.001 0.010 20.029 20.062 20.150 20.058 0.207 20.065 0.046 20.075
20.040 20.009 0.060 20.038 20.139 0.084 20.070 0.055 0.168 0.005
0.044 20.040 20.054 20.136 20.008 20.027 0.0465 20.057 0.136 0.039
GC0 0.268 0.173 20.109 0.201 0.135 0.230 0.096 0.064 20.031 0.116
0.000 0.034 20.030 20.036 0.023 0.090 0.038 0.170 0.218 0.048
0.207 0.028 20.027 20.000 0.090 0.237 0.087 0.048 0.109 0.139
0.156 20.038 0.266 0.117 0.177 0.074 0.463 20.004 0.138 20.093
0.144 20.197 0.295 20.055 0.069 0.039 0.135 0.019 0.016 0.449
0.301 0.192 0.109 0.037 0.168 0.136 0.052 0.029 20.074 0.078
GCz 0.218 0.277 0.138 0.142 0.029 0.254 0.278 0.0549 0.228 0.215
Treatment
group
GT{ 0.010 0.131 0.006 20.020 0.062 0.036 0.176 0.012 0.242 20.083
GT0 0.026 0.221 0.248 0.033 0.240 0.148 0.108 0.287 0.162 0.095
0.097 0.437 0.061 0.462 0.250 0.102 0.267 0.282 0.100 0.264
0.199 0.241 0.219 0.138 0.023 0.236 0.213 0.112 0.195 0.159
0.127 0.307 0.204 0.231 0.232 0.360 0.232 0.342 0.382 0.197
0.353 0.261 0.222 0.104 0.381 0.280 0.232 0.322 0.267 0.118
0.259 0.234 0.249 0.242 0.142 0.311 0.320 0.060 0.219 0.275
GTz 0.336 0.296 0.291 0.209 0.081 0.086 0.311 0.203 0.325 0.193
0.418 0.287 0.195 0.161 0.255 0.215 0.356 0.352 0.209 0.714
0.109 0.247 0.141 0.571 0.105 0.179 0.201 0.350 0.365 0.512
doi:10.1371/journal.pone.0048984.t004
Figure 4. The spread of observed (measured) treatment responses (vertical axis) of the participants in the simulated reference trial
across the six sub-groups (horizontal axis; see the ‘‘Study Design and Outcome Model’’ section).
doi:10.1371/journal.pone.0048984.g004
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only shows small random perturbations, as expected in any
experiment with a stochastic nature and is to be contrasted with
the plots in Figure 10 which show the changes in the two blinding
indexes throughout the experiment. Again, with the change in the
participants’ auxiliary data, both indexes also change in value. It is
insightful to observe that unlike in Experiment 3, in this instance
the values of the two indexes do not exhibit agreement on the
direction of change of the level of blinding. This reflects the
importance that the auxiliary data interpretation plays in the
methods of both James et al. and Bang et al.
Discussion
In the ‘‘Limitations of the Current Best Standards’’ section we
identified and discussed the key limitations of the currently
employed practices for assessing and accounting for imperfect
blinding in controlled clinical trials. Two key problem areas were
identified. The first of these is the separation of blinding
assessment using auxiliary trial data and the analysis of the main
outcome of the trial. The other major limitation of the current
practices is rooted in the interpretation of auxiliary data and
specifically the seemingly unavoidable need to model patients’
behaviour.
The separation of blinding assessment and main outcome
analysis, or inference atomization as we term it here, gives rise to a
number of undesirable consequences. For example, the assessment
of blinding of a trial can flip from successful to failed (or vice versa)
as a result of alteration in the feedback response of only a single
participant. Such sensitivity to small input differences means that
even an elementary change in the participants’ feedback may
result in all of the main trial data collected being thrown away.
This is clearly illustrated in Experiments 3 and 4 which
Figure 5. The three sub-group posteriors, p(DxD {), p(DxD 0) and p(DxD z), and the joint posterior p(DxD )~p(DxD {,D0,Dz). Also
marked is the mode of the posterior Dx~arg maxDx p(DxD )&0:107.
doi:10.1371/journal.pone.0048984.g005
Figure 6. Experiment 2. (a) Posteriors for the differential effect treatment Dx computed using the data Dg of each experimental sub-group
comprising control and treatment individuals matched by their feedback. (b) Posterior for the differential effect treatment Dx computed using all
available data D (~|gDg).
doi:10.1371/journal.pone.0048984.g006
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demonstrate the change in value of both blinding indexes as the
trial is gradually unblinded.
On the other hand, as long as the trial is deemed successful, no
information about the extent of blinding is propagated and
accounted for in the subsequent phase when the main trial data is
analyzed. For example, despite the change in feedback responses
between Experiment 1 and Experiment 2, and with it the change
in the values of blinding indexes, the entirety of the main trial data
in the two experiments was left unaltered. Since the assessment of
blinding is statistical in nature, it is not possible to identify
participants which may not have been blinded well enough. Thus,
data from a perfectly blinded trial is interpreted and processed in
the same way as of a barely sufficiently blinded trial (i.e. one with a
blinding index just exceeding a set threshold). This is in sharp
contrast with the proposed method. Because feedback responses
and the main trial data are analyzed in unison, the output of the
proposed method is unaffected by the unblinding in both
Experiment 3 and Experiment 4 (save for stochastic perturba-
tions).
Degenerate Cases
One of the key ideas behind the present method is that it is
meaningful to compare only the corresponding treatment and
control participant sub-groups, that is, sub-groups matched by
their auxiliary responses. As noted in the ‘‘Limitations of the
Current Best Standards’’ section, while a greater number of
subgroups may provide more precise auxilliary/blinding informa-
tion, the introduced partitioning of data decreases the statistical
Figure 7. Experiment 3. (a) Initial posterior (bold line) and the sequence of posteriors as ‘‘don’t know’’ responders in the treatment group are
progressively unblinded. Each next posterior plot corresponds to additional 10 ‘‘don’t know’’ respondents who become members of the sub-group
which correctly identified their group membership. (b) The maximum a posteriori estimate of the treatment effectiveness as the participants assigned
to the treatment group are progressively unblinded. Observe the robustness of the proposed approach, witnessed by little effect that unblinding has
on the estimate (standard deviation of the maximum a posteriori estimate: 0.0054); compare with Figure 8.
doi:10.1371/journal.pone.0048984.g007
Figure 8. Experiment 3. The values of the blinding indexes proposed by James et al. (blue line) and Bang et al. (red line), computed at each step of
the progressive unblinding of the participants assigned to the treatment group. As expected, both indexes dramatically change in value and in this
case agree that the level of blinding in the trial has decreased. Compare this with the robustness of the proposed approach in Figure 7.
doi:10.1371/journal.pone.0048984.g008
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strength of each comparison of the corresponding sub-groups
which results in a posterior with a wider spread. In an extreme
case, a particular sub-group may be empty. In other words, it is
possible that none of the participants of the treatment or the
control group expressed a particular belief regarding their
treatment assignment. Although this may appear as a problem
at first, a more careful examination of such cases reveals that this is
not so.
Firstly, note that whenever at least one pair of matching sub-
groups is non-empty, the proposed method is able to compute a
Figure 9. Experiment 4. The maximum a posteriori estimate of the treatment effectiveness as the participants assigned to both the treatment and
the control groups are progressively unblinded (compare with the previous, asymmetric blinding experiment and Figure 7). As before, the proposed
method exhibits remarkable robustness.
doi:10.1371/journal.pone.0048984.g009
Figure 10. Experiment 4. The values of the blinding indexes proposed by James et al. (blue line) and Bang et al. (red line), computed at each step
of the progressive unblinding of the participants assigned to the treatment group. While both indexes again dramatically change in value,
interestingly they also show disagreement on the direction of change in blinding. This is a consequence of the difference in the underlying
assumptions used to interpret the participants’ auxiliary data. Compare this with the robustness of the proposed approach in Figure 9.
doi:10.1371/journal.pone.0048984.g010
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meaningful estimate of differential treatment effectiveness. In
instances when there are no non-empty matching sub-groups, the
nature of degeneracy can provide useful insight to the clinician.
The absence of individuals in the GTz sub-group may indicate
that the participants assigned to the treatment group have either
been poorly blinded but misidentified the received treatment, or
that the treatment was vastly ineffective and was recognized as
such by the participants assigned to it. Similarly, the absence of
individuals in the GT{ sub-group may indicate that the
participants assigned to the treatment group have either been
poorly blinded and correctly identified the received treatment, or
that the treatment was obviously effective. In all cases, because
degenerate data is trivial to recognize, the clinician is immediately
made aware of the presence of a major flaw in the experimental
design. The clinician can then identify the cause of degeneration
using own knowledge of the administered interventions, and the
statistics of both auxiliary responses and trial outcomes.
Further Clinical Insight
In the ‘‘Inference’’ section we derived posteriors corresponding
both to only a single pair of corresponding sub-groups in Equation
(13) and to the entirety of data, that is, all sub-groups in Equation
(15). While the latter of these is of primary interest, the clinician
can derive further useful insight into the nature of studied
treatment by comparative examination of sub-group posteriors
too.
The least interesting case is when the sub-group posteriors and
the total posterior exhibit similar characteristics (e.g. the location
of the mode). However, consider the case when that is not so. For
example, let us say that the posterior corresponding to the two
matching ‘‘don’t know’’ subgroups has the mode near Dx&0 and
the total posterior has a decidedly positive mode (with suitably
small standard deviations, to make the observation statistically
significant). This could indicate that there may be so-called ‘‘non-
responders’’ in the treatment group, i.e. individuals which did not
respond positively to the treatment which in most people does
produce a positive result [13,14]. Similar arguments can be made
by considering differences between other sub-group posteriors.
Ultimately, the exact interpretation is in the hands of the clinicians
who should use their insight into the nature of the administered
interventions to infer further information of this type.
Summary and Conclusions
This paper examined the problem of assessing the extent of
blindness in a clinical trial. Currently, this is achieved by collecting
auxiliary data in the form of a questionnaire which asks the trial
participants which group (treatment or control) they think they
were assigned to. Methods in use today employ this data to
compute a statistic, a blinding index, which is then compared
against a threshold leading to a crisp positive or negative decision
on whether the trial was sufficiently blinded.
Our first major contribution was to demonstrate a series of flaws
in blinding index based approaches. The main flaws are: (i) the
presence of ad hoc free parameters in the statistical model used to
derive a blinding index, (ii) the non-universality of the assumptions
used to interpret the auxiliary questionnaire responses, (iii) the
sensitivity of blinding assessment to small changes in participants’
questionnaire responses, and (iv) the sequential separation of
inference concerning the extent of trial blindness and the
assessment of differential effectiveness of the treatment. Thus, a
novel framework was proposed.
We too adopt an auxiliary questionnaire of the same form as
currently in use but describe a statistical model which does not rely
on the assumptions made in previous work that lead to the
aforementioned difficulties. At the centre of the idea is that the
comparison of the treatment and control groups should be done in
like-for-like fashion, giving rise to the partitioning of participants
into sub-groups, each sub-group sharing the same intervention and
auxiliary responses. A Bayesian framework was used to interpret
jointly the auxiliary and trial outcome data, giving the clinician a
meaningful and readily understandable end result. The effective-
ness of our method was demonstrated empirically in a simulation
study, which showed its robustness in a variety of scenarios. In
addition, it was shown how our method can be used to reveal
additional important information regarding the effectiveness of the
trial, such as groups of non-responders.
Lastly, our work strongly highlights the need for open reporting
of trial results. Specifically, although the proposed method uses the
same type of auxiliary data as the previously proposed methods, it
is necessary that the auxiliary and trial outcome responses are
matched by individual participant, rather than aggregated. At
present, this detail is not widely reported nor readily made
available even upon request.
Derivation of the Key Equations
Consider two matching sub-groups GTg and GCg, one
corresponding to the treatment group and one to the control
group, such as GTz and GCz. Our goal is to infer the posterior
distribution p(DxD g) for the differential effect of treatment Dx
(the difference in the effectiveness between the treatment and the
control group) given the main trial data Dg (the observed
effectiveness of target and control interventions in the two
subgroups). The entire data corpus Dg consists of responses of
the control subgroup DCg~fx(1)Cg, . . . ,x(nCg)Cg g and the responses of
the corresponding treatment subgroup DTg~fx(1)Tg, . . . ,x(nTg)Tg g
where nTg is the number of participants in GTg and nCg the
number of participants in GCg. Using Bayes rule, the posterior can
be expressed in terms of likelihood P(Dg D x) for Dx and the priors
p(Dx) and p(Dg):
p(DxD g)~
P(Dg D x) p(Dx)
p(Dg)
ð20Þ
Assuming an uninformed prior for p(Dx) and observing that in this
context p(Dg) is merely a weighting constant, Equation (20) can be
simplified to:
p(DxD g)!p(Dg D x) ð21Þ
As usual, we assume that the effectiveness response of each trial
subgroup obeys a normal distribution. Let the mean outcome for
the control subgroup be mCg and consequently the mean of the
corresponding treatment subgroup mCgzDx, and the standard
deviation of outcomes within the sub-groups sg. Since we again
have no universal reason to expect one value of mCg or sg over
another, that is, no means of formulating an informed prior on
mCg and sg, we use the appropriate uninformed priors which are
in this case [15]:
p(mCg)!1 and p(sg)!1=sg ð22Þ
Note that these are improper priors (i.e. they do not integrate to
unity). Using a Bayesian approach whereby the unknown latent
variables of the model are integrated out:
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p(DxD g)!p(Dg D x)~ ð23Þ
ð
mCg
ð
sg
p(Dg D Dx,mCg,sg) p(mCg) p(sg)dsg dmCg~ ð24Þ
ð
mCg
ð
sg
p(Dg D Dx,mCg,sg)
1
sg
dsg dmCg~ ð25Þ
ð
mCg
ð
sg
1
sg
exp { 1
2s2g
PnCg
i (x
(i)
Cg{mCg)
2{
PnTg
j (x
(2)
Tg{mCg{Dx)
2
h i 
(2p)
nCgznTg
2 :s
nCgznTg
g
dsgdmCg
ð26Þ
Now consider the term in the brackets of the numerator’s
exponent in Equation (26). This term can be written as a sum of a
square and a constant:
XnCg
i
(x
(i)
Cg{mCg)
2{
XnTg
j
(x
(j)
Tg{mCg{Dx)
2
:(agmCg{bg)
2zcg
ð27Þ
Expanding the left-hand size and equating the coefficients
corresponding to different powers of mCg gives the following
values for the unknown variables ag, bg and cg on the right-hand
size of the equality:
ag~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
nCgznTg
p ð28Þ
bg~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
nCgznTg
p
PnCg
i x
(i)2
Cg{
PnTg
j (x
(j)
Tg{Dx)
2
ð29Þ
cg~
XnCg
i~1
x
(1)2
i z
XnTg
j~1
(x
(2)
j {Dx)
2
{
PnCg
i~1 x
(i)
Cgz
PnTg
j~1 (x
(j)
Tg{Dx)
h i2
nCgznTg
ð30Þ
Continuing to use constants a, b and c for clarity, Equation (26)
can be written as:
p(DxD g)!
ð
mCg
ð
sg
1
sg
expf{ 1
2s2g
(agmCg{bg)
2{
cg
2s2g
g
(2p)
nCgznTg
2 :s
nCgznTg
g
dsgdmCg ð31Þ
Re-arranging the right-hand size further and integrating out the
Gaussian gives:
p(Dx j Dg)!
ð
mCg
ð
sg
1
sg
expf{ (mCg{bg=ag )
2
2(sg=ag)2
g:expf{ cg
2s2g
g
(2p)
nCgznTg
2 :s
nCgznTg
g
dsgdmCg~
ð32Þ
ð
sg
1
sg
expf{cg=2s2gg:(2p)1=2 sgag
	 

(2p)
nCgznTg
2 :s
nCgznTg
g
dsg~ ð33Þ
ð
sg
(2p)
1{nCg{nTg
2
exp {cg=2s
2
g
n o
ag:s
nCgznTg
g
dsg ð34Þ
Note that the expression in Equation (34) has the functional form
of the inverse gamma distribution:
(yg; ag,bg)~
b
ag
g
C(ag)
1
yagz1
exp {
bg
yg
 
ð35Þ
where
ag~
nCgznTg{1
2
bg~cg=2 yg~s
2
g ð36Þ
Thus, re-writing Equation (35) and remembering that the inverse
gamma distribution must integrate to unity (being a probability
density function), gives:
p(DxD g)!
(2p)
1{nCg{nTg
2
2ag
ð
y
C
nCgznTg{1
2
	 

cg
2
 nCgznTg{1
2
(yg; ag,bg)dyg!ð37Þ
c
{
nCgznTg{1
2
g
ð
yg
(yg; ag,bg)dyg~c
{
nCgznTg{1
2
g ð38Þ
which is the exactly the expression in Equation 13 introduced in
the main text in the ‘‘Inference’’ section. QED.
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